Japan Blood Glucose Monitoring Market Size, Share & Forecast 2026-2033

Overview

Japan blood glucose monitoring market was valued at USD 0.79 billion in 2025 and is projected to reach USD 1.33 billion by 2033, growing at a CAGR of 6.8% during the forecast period. While the increasing prevalence of diabetes continues to underpin market demand, the industry is increasingly being shaped by digital healthcare transformation, population ageing, connected medical devices, and home-based chronic disease management.

Japan has one of the world's oldest populations, with nearly one-third of its citizens aged 65 years or above. As diabetes prevalence rises alongside population ageing, healthcare providers are placing greater emphasis on continuous disease monitoring outside traditional hospital settings. Self-monitoring blood glucose (SMBG) devices remain widely used due to their affordability and reimbursement support, while continuous glucose monitoring (CGM) systems are rapidly expanding as clinicians seek more comprehensive glucose data to improve treatment outcomes.

The market is also undergoing rapid digitalization. Modern glucose monitoring devices increasingly integrate with smartphones, cloud-based platforms, artificial intelligence, and remote patient monitoring systems that enable physicians to monitor patients between hospital visits. Collaborations such as Roche Diabetes Care Japan and Astellas Pharma's BlueStar-integrated Accu-Chek platform, together with digital behavior-modification initiatives launched by Provigate and H.U. Group Research Institute, illustrate Japan's shift toward connected diabetes management rather than simple glucose measurement.

Government healthcare policies further strengthen market growth through nationwide health screening programs, universal insurance coverage, and continued investment in preventive healthcare. At the same time, manufacturers continue introducing smaller sensors, improved CGM accuracy, longer sensor wear time, and enhanced smartphone connectivity, making glucose monitoring more convenient for both physicians and patients. Together, demographic trends, technological innovation, digital healthcare integration, and supportive reimbursement policies are expected to sustain healthy growth across Japan's blood glucose monitoring market throughout the forecast period.

Drivers

Growing Product Innovation in Japan

Innovation is playing a central role in driving the growth of the blood glucose monitoring market in Japan, as companies increasingly focus on integrating advanced technologies, personalized care, and therapeutic insights to meet the evolving needs of diabetes patients. Product innovation is accelerating the evolution of Japan's blood glucose monitoring market as manufacturers integrate digital therapeutics, AI, smartphone connectivity and personalized diabetes management into traditional monitoring devices.

In May 2025, Poxel announced the presentation of 15 new clinical and scientific studies on TWYMEEG® at the Japan Diabetes Society 2025 meeting. These findings highlight TWYMEEG®’s efficacy, safety profile, and dual mechanism of action, as well as its effectiveness across a broad spectrum of patients, including those with renal impairment. The data, supported by Sumitomo Pharma, further reinforce the drug's value both as a monotherapy and in combination treatment settings. Such clinical advancements are critical in building trust among healthcare providers and patients, while also supporting the broader commercialization and adoption of innovative diabetes therapies that complement glucose monitoring tools.

Meanwhile, technological convergence is becoming increasingly prominent in the Japanese diabetes care market. In March 2023, Astellas Pharma entered into an agreement with Roche Diabetes Care Japan to co-develop and commercialize the Accu-Chek® Guide Me blood glucose monitoring system, integrated with BlueStar®, a digital health solution created by Welldoc. This collaboration aims to bring a combined medical product to the Japanese market, one that not only tracks blood glucose levels but also offers intelligent, real-time support through a digital platform. Astellas and Welldoc are working toward achieving regulatory approval and reimbursement, signaling a shift toward connected health solutions that provide continuous, data-driven diabetes management.

These advancements reflect a broader trend in Japan’s healthcare system toward digitalization and precision medicine. By integrating therapeutics with diagnostics and behavioral guidance, companies are creating comprehensive solutions that align with both clinical needs and patient lifestyles. As a result, the blood glucose monitoring market is evolving beyond traditional test strips and meters into a more sophisticated, multi-faceted ecosystem that supports proactive, personalized care. This ongoing innovation is expected to accelerate market growth and enhance the quality of diabetes care throughout Japan.

Government Healthcare Initiatives and Japan’s Aging Population Driving Diabetes Management Investment

Japan’s rapidly ageing population and the government’s proactive healthcare policy framework are creating sustained structural demand for blood glucose monitoring solutions. Japan has one of the world’s highest proportions of elderly citizens, with the over-65 population exceeding 29% of the total—a demographic that carries significantly higher diabetes prevalence and requires frequent blood glucose monitoring for effective chronic disease management. The Japanese government’s national diabetes prevention and management programs, integrated within its universal health insurance system, provide reimbursement coverage for blood glucose monitoring devices and test strips for diagnosed diabetic patients, creating a stable and government-supported demand base.

Japan’s Ministry of Health, Labour and Welfare actively promotes early diabetes detection and management through national health checkup programs (Tokutei Kensin) that screen millions of adults annually for metabolic risk factors including elevated blood glucose. Patients identified through these programs are directed toward continuous monitoring and lifestyle management, supporting sustained device adoption. The integration of digital health platforms with glucose monitoring—as exemplified by the Astellas Pharma and Roche Diabetes Care Japan collaboration announced in March 2023 to co-develop and commercialize the Accu-Chek Guide Me system with the BlueStar digital health solution—reflects the Japanese government’s broader push toward connected health and digital therapeutics integration.

Restraint

High Cost of Continuous Glucose Monitoring Systems and Reimbursement Limitations

Despite strong growth fundamentals, the Japan blood glucose monitoring market faces meaningful constraints from the high cost of continuous glucose monitoring (CGM) systems relative to traditional self-monitoring blood glucose (SMBG) devices, and limitations in insurance reimbursement coverage for CGM among all categories of diabetic patients. CGM sensors and transmitters require regular replacement—typically every 10-14 days per sensor—creating ongoing out-of-pocket costs for patients whose coverage is limited or who do not qualify for full reimbursement under Japan’s national health insurance system.

Japan’s reimbursement framework for CGM has historically been more restrictive than in the U.S. and parts of Europe, with coverage primarily available for insulin-dependent Type 1 diabetes patients and, more recently, for certain Type 2 diabetes patients on intensive insulin therapy. The majority of Type 2 diabetes patients—who represent the largest segment of Japan’s diabetic population—manage their condition through oral medications and may not qualify for CGM reimbursement, limiting adoption to self-pay or partial reimbursement pathways. Additionally, the development of non-invasive blood glucose monitoring technologies—such as the near-infrared light method demonstrated by Hamamatsu Photonics researchers in March 2024—remains in early development stages without regulatory approval, meaning the commercial transition to truly non-invasive monitoring is still years away.

Japan Blood Glucose Monitoring Market Trends & Opportunities

AI and Digital Diabetes Management Platforms Are Becoming the Next Competitive Differentiator

Japan is rapidly integrating artificial intelligence, connected medical devices, and digital therapeutics into diabetes management. Rather than simply recording glucose values, next-generation monitoring platforms provide personalized recommendations, medication reminders, behavioral coaching, and physician connectivity through smartphone applications, enabling more proactive disease management.

Japan's digital health ecosystem is expanding rapidly, supported by government initiatives under the Society 5.0 strategy and the Ministry of Health, Labour and Welfare's continued promotion of telemedicine and digital healthcare. In 2025, approximately 8.97 million adults in Japan (8.1% of the adult population) were living with diabetes (IDF), creating a large addressable market for connected monitoring solutions. At the same time, smartphone penetration exceeds 90% among Japanese consumers, providing the infrastructure necessary for cloud-connected glucose monitoring and remote patient management.

Manufacturers are increasingly combining blood glucose monitoring with AI-powered analytics and digital therapeutics. Roche Diabetes Care Japan and Astellas Pharma continue developing the Accu-Chek Guide Me platform integrated with BlueStar digital therapeutics, while Kakao Healthcare announced plans during 2025 to introduce its AI-powered diabetes management platform into Japan using Dexcom CGM technology. As reimbursement policies gradually support digital health integration, software-enabled diabetes management is expected to become a major competitive differentiator.

Continuous Glucose Monitoring Is Gradually Replacing Traditional Finger-Prick Monitoring

Continuous glucose monitoring (CGM) represents the fastest-growing segment of Japan's blood glucose monitoring market as healthcare providers increasingly prioritize continuous glucose visibility over intermittent finger-prick testing. Unlike traditional self-monitoring blood glucose devices, CGM systems automatically measure glucose levels every few minutes, allowing physicians to monitor glucose trends, detect hypoglycemia earlier, and improve treatment decisions. CGM devices generate nearly 288 glucose readings per day compared with only 4–8 finger-stick measurements using SMBG.

Growing clinical evidence is also supporting wider adoption. In March 2025, researchers at Nagoya University reported that CGM devices could improve driving safety among diabetic patients by providing real-time hypoglycemia alerts. Some of the leading manufacturers including Abbott, Dexcom, Medtronic, and Roche continue improving sensor accuracy, smartphone connectivity, and cloud-based monitoring capabilities while extending sensor wear duration. As reimbursement expands and device costs gradually decline, CGM adoption is expected to accelerate across both hospital and home-care settings.

Home-Based Diabetes Care Continues Expanding Across Japan

Japan's rapidly ageing population is accelerating the transition from hospital-based diabetes management toward home-based monitoring. According to Japan's Ministry of Internal Affairs and Communications, people aged 65 years and above account for approximately 29% of the country's population, one of the highest proportions globally. This demographic shift is increasing demand for convenient glucose monitoring technologies that support independent disease management.

Government policies promoting preventive healthcare, together with expanded telemedicine services and remote patient monitoring, are encouraging patients to manage diabetes from home while maintaining regular physician oversight. Connected blood glucose meters, smartphone-enabled CGM systems, and cloud-based monitoring platforms allow healthcare professionals to review glucose trends remotely, reducing unnecessary hospital visits and improving treatment adherence. The growing preference for home healthcare is creating opportunities for manufacturers offering compact monitoring devices, wearable sensors, mobile applications, and integrated diabetes management ecosystems that combine monitoring, analytics, and remote clinical support.

Segment Analysis

Japan blood glucose monitoring industry is segmented based on product, testing type, patient care setting, application and region.

Fingertip Testing Segment Held A Significant Market Share

Fingertip testing segment held a market revenue share of more than 53.3% in 2025. The fingertip testing segment continues to grow despite emerging innovations in noninvasive technologies, primarily due to its reliability, accessibility, and widespread clinical acceptance. Finger-prick testing remains the gold standard for accurate, real-time blood glucose readings, especially in clinical settings and among individuals who require frequent monitoring to manage their condition effectively. Its proven performance and compatibility with insurance reimbursement systems in Japan ensure that it remains a trusted option for both healthcare providers and patients.

While there is growing interest in developing less invasive alternatives, such as the method introduced in March 2024 by a research team led by Tomoya Nakazawa from Hamamatsu Photonics, these technologies are still in the early stages of development. The team’s novel approach utilizes near-infrared (NIR) light to estimate blood glucose levels noninvasively by analyzing the phase delay between oxyhemoglobin and deoxyhemoglobin signals—a metabolic indicator. Their study, which showed a promising correlation between this new index and blood glucose levels using commercial smartwatches and smartphones, represents a major technological breakthrough. However, since clinical testing on diabetic patients is still pending, the method has not yet achieved regulatory approval or widespread adoption.

As non-invasive technologies mature and move closer to commercialization, fingertip testing continues to benefit from its established infrastructure, user familiarity, and integration with broader diabetes management systems. Patients and providers still rely on its precision for daily monitoring, medication adjustment, and emergency response. Additionally, fingertip devices are increasingly being enhanced with digital features, including data logging and app integration, to offer more personalized and connected care experiences.

Continuous Glucose Monitoring Systems Are Emerging as the Fastest-Growing Product Segment

Continuous glucose monitoring (CGM) systems are expected to register the highest growth rate in Japan's blood glucose monitoring market as healthcare providers increasingly prioritize proactive diabetes management over intermittent glucose testing. Continuous glucose monitoring (CGM) systems are becoming one of the most advanced diabetes monitoring devices in Japan, supported by improvements in sensor accuracy, smartphone connectivity, and digital diabetes management platforms.

Unlike conventional self-monitoring blood glucose devices that require multiple daily finger-prick tests, CGM systems continuously measure interstitial glucose levels throughout the day, enabling patients and clinicians to monitor glucose variability, detect hypoglycemia earlier, and optimize insulin therapy. Growing clinical evidence supporting improved glycemic control, combined with expanding smartphone connectivity and cloud-based monitoring, is accelerating adoption across both hospitals and home-care settings. Collaborations such as Roche Diabetes Care Japan's Accu-Chek Guide Me platform integrated with BlueStar digital therapeutics, Kakao Healthcare's planned deployment of Dexcom-powered AI diabetes management services, and Biolinq's technology partnership with Taisho Pharmaceutical highlight increasing investment in next-generation connected glucose monitoring solutions. In addition, the March 2025 Nagoya University study demonstrating improved road safety among diabetic drivers using CGM further strengthens physician confidence in continuous monitoring technologies. As reimbursement gradually expands and sensor accuracy continues improving, CGM systems are expected to capture an increasing share of Japan's diabetes monitoring market over the forecast period. 

Key Developments

·         In May 2026, Abbott received CE Mark approval for Libre Duo, the world's first dual glucose-and-ketone continuous monitoring system. This expands Abbott's Libre ecosystem and supports future diabetes management innovation.

·         In March 2025, A Japanese study conducted by a team from Nagoya University Graduate School of Medicine found that the use of continuous glucose monitoring (CGM) devices, equipped with sensors that alert diabetics when their blood sugar levels drop, can potentially make them safer on the road.

·         In May 2025, Kakao Healthcare Corp. company announced plans to introduce its artificial intelligence-powered continuous glucose monitoring (CGM) application, PASTASearch drug, to the Japanese market through a newly established subsidiary. This move represents a significant milestone in the South Korean company's strategy to expand its global footprint in digital health solutions.